140 related articles for article (PubMed ID: 15603852)
1. Efficacy of the third-generation bisphosphonate, zoledronic acid alone and combined with anti-cancer agents against small cell lung cancer cell lines.
Matsumoto S; Kimura S; Segawa H; Kuroda J; Yuasa T; Sato K; Nogawa M; Tanaka F; Maekawa T; Wada H
Lung Cancer; 2005 Jan; 47(1):31-9. PubMed ID: 15603852
[TBL] [Abstract][Full Text] [Related]
2. Zoledronic acid is unable to induce apoptosis, but slows tumor growth and prolongs survival for non-small-cell lung cancers.
Li YY; Chang JW; Chou WC; Liaw CC; Wang HM; Huang JS; Wang CH; Yeh KY
Lung Cancer; 2008 Feb; 59(2):180-91. PubMed ID: 17900752
[TBL] [Abstract][Full Text] [Related]
3. Synergistic inhibitory activity of zoledronate and paclitaxel on bone metastasis in nude mice.
Lu S; Zhang J; Zhou Z; Liao ML; He WZ; Zhou XY; Li ZM; Xiang JQ; Wang JJ; Chen HQ
Oncol Rep; 2008 Sep; 20(3):581-7. PubMed ID: 18695909
[TBL] [Abstract][Full Text] [Related]
4. Zoledronic acid, a third-generation bisphosphonate, inhibits cellular growth and induces apoptosis in oral carcinoma cell lines.
Tamura T; Shomori K; Nakabayashi M; Fujii N; Ryoke K; Ito H
Oncol Rep; 2011 Apr; 25(4):1139-43. PubMed ID: 21249320
[TBL] [Abstract][Full Text] [Related]
5. Anti-tumor effect of bisphosphonate (YM529) on non-small cell lung cancer cell lines.
Koshimune R; Aoe M; Toyooka S; Hara F; Ouchida M; Tokumo M; Sano Y; Date H; Shimizu N
BMC Cancer; 2007 Jan; 7():8. PubMed ID: 17222343
[TBL] [Abstract][Full Text] [Related]
6. Combined therapy with a new bisphosphonate, minodronate (YM529), and chemotherapy for multiple organ metastases of small cell lung cancer cells in severe combined immunodeficient mice.
Yano S; Zhang H; Hanibuchi M; Miki T; Goto H; Uehara H; Sone S
Clin Cancer Res; 2003 Nov; 9(14):5380-5. PubMed ID: 14614023
[TBL] [Abstract][Full Text] [Related]
7. Zoledronic acid treatment impairs protein geranyl-geranylation for biological effects in prostatic cells.
Goffinet M; Thoulouzan M; Pradines A; Lajoie-Mazenc I; Weinbaum C; Faye JC; Séronie-Vivien S
BMC Cancer; 2006 Mar; 6():60. PubMed ID: 16539721
[TBL] [Abstract][Full Text] [Related]
8. The bisphosphonate, zoledronic acid, induces apoptosis of breast cancer cells: evidence for synergy with paclitaxel.
Jagdev SP; Coleman RE; Shipman CM; Rostami-H A; Croucher PI
Br J Cancer; 2001 Apr; 84(8):1126-34. PubMed ID: 11308265
[TBL] [Abstract][Full Text] [Related]
9. The activity of zoledronic Acid on neuroblastoma bone metastasis involves inhibition of osteoclasts and tumor cell survival and proliferation.
Peng H; Sohara Y; Moats RA; Nelson MD; Groshen SG; Ye W; Reynolds CP; DeClerck YA
Cancer Res; 2007 Oct; 67(19):9346-55. PubMed ID: 17909043
[TBL] [Abstract][Full Text] [Related]
10. Zoledronic acid but not somatostatin analogs exerts anti-tumor effects in a model of murine prostatic neuroendocrine carcinoma of the development of castration-resistant prostate cancer.
Hashimoto K; Masumori N; Tanaka T; Maeda T; Kobayashi K; Kitamura H; Hirata K; Tsukamoto T
Prostate; 2013 Apr; 73(5):500-11. PubMed ID: 22996996
[TBL] [Abstract][Full Text] [Related]
11. Combined effects of bisphosphonate and radiation on osteosarcoma cells.
Ryu K; Murata H; Koto K; Horie N; Matsui T; Nishigaki Y; Sakabe T; Takeshita H; Itoi M; Kimura S; Ashihara E; Maekawa T; Fushiki S; Kubo T
Anticancer Res; 2010 Jul; 30(7):2713-20. PubMed ID: 20683003
[TBL] [Abstract][Full Text] [Related]
12. The level of ATP analog and isopentenyl pyrophosphate correlates with zoledronic acid-induced apoptosis in cancer cells in vitro.
Mitrofan LM; Pelkonen J; Mönkkönen J
Bone; 2009 Dec; 45(6):1153-60. PubMed ID: 19699819
[TBL] [Abstract][Full Text] [Related]
13. The bisphosphonate zoledronic acid inhibits the growth of HCT-116 colon carcinoma cells and induces tumor cell apoptosis.
Sewing L; Steinberg F; Schmidt H; Göke R
Apoptosis; 2008 Jun; 13(6):782-9. PubMed ID: 18437576
[TBL] [Abstract][Full Text] [Related]
14. Increased anti-tumour effects of doxorubicin and zoledronic acid in prostate cancer cells in vitro: supporting the benefits of combination therapy.
Clyburn RD; Reid P; Evans CA; Lefley DV; Holen I
Cancer Chemother Pharmacol; 2010 Apr; 65(5):969-78. PubMed ID: 19730863
[TBL] [Abstract][Full Text] [Related]
15. Inhibitory effects of a new bisphosphonate, minodronate, on proliferation and invasion of a variety of malignant bone tumor cells.
Kubo T; Shimose S; Matsuo T; Tanaka K; Yasunaga Y; Sakai A; Ochi M
J Orthop Res; 2006 Jun; 24(6):1138-44. PubMed ID: 16705696
[TBL] [Abstract][Full Text] [Related]
16. Anticancer effects of zoledronic acid against human osteosarcoma cells.
Kubista B; Trieb K; Sevelda F; Toma C; Arrich F; Heffeter P; Elbling L; Sutterlüty H; Scotlandi K; Kotz R; Micksche M; Berger W
J Orthop Res; 2006 Jun; 24(6):1145-52. PubMed ID: 16602111
[TBL] [Abstract][Full Text] [Related]
17. Anti-angiogenic property of zoledronic acid by inhibition of endothelial progenitor cell differentiation.
Yamada J; Tsuno NH; Kitayama J; Tsuchiya T; Yoneyama S; Asakage M; Okaji Y; Shuno Y; Nishikawa T; Tanaka J; Takahashi K; Nagawa H
J Surg Res; 2009 Jan; 151(1):115-20. PubMed ID: 18619615
[TBL] [Abstract][Full Text] [Related]
18. Combined effects of a third-generation bisphosphonate, zoledronic acid with other anticancer agents against murine osteosarcoma.
Horie N; Murata H; Kimura S; Takeshita H; Sakabe T; Matsui T; Maekawa T; Kubo T; Fushiki S
Br J Cancer; 2007 Jan; 96(2):255-61. PubMed ID: 17242698
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of the third-generation bisphosphonate risedronate alone and in combination with anticancer drugs against osteosarcoma cell lines.
Murayama T; Kawasoe Y; Yamashita Y; Ueno Y; Minami S; Yokouchi M; Komiya S
Anticancer Res; 2008; 28(4B):2147-54. PubMed ID: 18751388
[TBL] [Abstract][Full Text] [Related]
20. Zoledronic acid activates the DNA S-phase checkpoint and induces osteosarcoma cell death characterized by apoptosis-inducing factor and endonuclease-G translocation independently of p53 and retinoblastoma status.
Ory B; Blanchard F; Battaglia S; Gouin F; Rédini F; Heymann D
Mol Pharmacol; 2007 Jan; 71(1):333-43. PubMed ID: 17050806
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
